OncoMatch/Clinical Trials/NCT06756308
A Study of Enasidenib in People With T-Cell Lymphoma
Is NCT06756308 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Enasidenib and Rituximab for t-cell lymphoma.
Treatment: Enasidenib · Rituximab — The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: IDH2 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic anti-cancer therapy
disease must have relapsed or progressed after at least one systemic therapy
Cannot have received: enasidenib (enasidenib)
Prior use of enasidenib
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0 K/μL or ≥0.5 K/μL if due to lymphoma; Platelet count ≥80 K/μl or ≥50 K/μl if due to lymphoma
Kidney function
Calculated creatinine clearance ≥30 mL/min by MDRD
Liver function
Total bilirubin ≤1.5x ULN or ≤3x ULN if documented hepatic involvement with lymphoma, or ≤5x ULN if history of Gilbert's syndrome; AST and ALT ≤ 3x ULN; ≤ 5x ULN if due to lymphoma involvement
Laboratory criteria: i) Absolute neutrophil count ≥1.0 K/μL or ≥0.5 K/μL if due to lymphoma ii) Platelet count ≥80 K/μl or ≥50 K/μl if due to lymphoma iii) Calculated creatinine clearance ≥30 mL/min by MDRD iv) Total bilirubin ≤1.5x ULN or ≤3x ULN if documented hepatic involvement with lymphoma, or ≤5x ULN if history of Gilbert's syndrome; AST and ALT ≤ 3x ULN; ≤ 5x ULN if due to lymphoma involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute (Data Collection Only) · Boston, Massachusetts
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify